ACT-based clinical trials for glioma*Abbreviations used in this table. AA: anaplastic astrocytoma; CR: complete response; DTH: delayed-type hypersensitivity; GBM: gliobrastoma; Gr2: WHO grade II glioma; Gr3: WHO grade III glioma; HGG: high-grade glioma; mo: month(s); OS: overall survival; PFS: progression-free survival; PR: partial response; SD: stable disease.
1. Introduction
Cancer immunotherapy is the use of the immune system to reject cancers. The main premise is to harness the patient's immune system to attack the malignant tumor cells. This area of research has made tremendous progresses, and the United States Food and Drug Administration recently approved a vaccine for prostate cancers as the first approval for vaccines against non-viral cancers (Kantoff et al., 2010). However, when it comes to central nervous system (CNS) tumors, while early phase immunotherapy trials showed encouraging outcomes, the immunological microenvironment of the CNS and tumors arising in the CNS is still believed to be suboptimal for sufficient antitumor immune responses to mediate clinically-meaningful changes
2. Immunology of gliomas
2.1. Immunology of CNS
For many decades, the brain has been considered an immune-privileged site due to the presence of a blood brain barrier (BBB) and the lack of lymphatics (Ransohoff et al., 2003). More recent studies have revealed crucial components involved in the process of leukocyte migration towards the CNS and the mechanisms of neuroinflammatory reactions in the CNS (Ransohoff et al., 2003). This section will focus on three key issues of CNS immunology: 1) factors limiting inflammation in the CNS, 2) antigen-specific immune response in the CNS, and 3) immune cell trafficking towards the CNS. In-depth understanding of these aspects will allow us to gain a framework to improve current treatment strategies harnessing the immune system to treat brain tumors.
2.1.1. Factors limiting inflammation in the CNS
Cells composing the CNS are extremely sensitive to the toxic effects of exogenous substances. Therefore, the CNS and the neurovasculature system therein have evolved specialized mechanisms to control both molecular and cellular migration into and out of the CNS parenchyma and cerebral spinal fluid (CSF). Capillary endothelial cells in the CNS are termed the BBB due to their ability to restrict passive diffusion and maintain low pinocytotic activity, and neuroimmunologists synonymously use the term BBB to describe both the capillary and post capillary vessels, the latter of which is the site of T-cell migration into the brain (Ransohoff et al., 2003). This "barrier" results from the selectivity of the tight junctions (TJs) between endothelial cells in the CNS vessels that restrict the passage of large hydrophilic molecules (i.e. peptides and proteins) and cells (Abbott et al., 2006).
Many extracellular proteins have been studied as TJ proteins: primarily the occludin, claudin, and junctional adhesion molecule (JAM) families. Experimental characterization of each has shown that mice carrying a null mutation in the occludin gene develop normal TJs whereas claudins have been shown to be independently sufficient for TJ formation (Engelhardt, 2008), suggesting the importance of claudins in TJ formation and regulation. Additionally, intravenous injection of monoclonal antibodies blocking JAM into mice inhibits leukocyte accumulation in CSF and brain parenchyma presumably through blocking leukocyte transmigration at the BBB (Engelhardt, 2008).
2.1.2. Induction of Immune responses to CNS antigens
The classic paradigm of specific immune activation is achieved through antigen uptake by antigen-presenting cells (APCs), which migrate to the lymph nodes via draining lymphatics where APCs subsequently activate T-cells. In the systemic immune system, dendritic cells (DCs) are considered to be the most potent APCs. In the CNS, a variety of cell populations have been postulated as primary CNS APCs, including vascular endothelial cells, smooth muscle cells, astrocytes, perivascular macrophages, choroid plexus epithelial cells, neurons, and DCs (Dunn et al., 2007). Among them, microglia has been proposed to be the primary resident APCs in the CNS (Aloisi, 2001).
Presentation of CNS antigens can occur through multiple mechanisms (Walker, P. R. et al., 2003): 1) APC uptake antigen within the CNS and migrate to lymph nodes to present antigens; 2) antigen drains to lymph nodes where APCs take them up to present, and 3) cells that express the antigen directly drain to lymph nodes and present their own antigen (direct presentation as opposed to cross presentation by DCs). Indeed, DCs injected in brain tumors have been shown to migrate to the cervical lymph nodes (CLNs) (Dunn et al., 2007). In addition, autoantigens from brain lesions have been shown to drain to CLNs in both primate models of experimental allergic encephalomyelitis and human multiple sclerosis (de Vos et al., 2002). Concurrently, it has been shown that tumor-specific T-cells can be primed in CLNs in murine glioma models (Fujita et al., 2009; Kuwashima et al., 2005; Okada, N. et al., 2005).
2.1.3. Migration of immune cells towards the CNS
Lymphocytes traffic to the CNS through the following 4 steps: 1) tethering/rolling, 2) activation, 3) adhesion, and 4) transmigration (Engelhardt, 2008). Interactions between carbohydrates on leukocytes and adhesion molecules (usually selectins) on endothelial cells slow down the leukocytes. Chemokines (e.g. CXCL10) are released from a site of inflammation and form a concentration gradient in endothelial membrane and attract responsible leukocytes such as activated T-cells (Fujita et al., 2009; Nishimura et al., 2006). At a reduced velocity, the leukocytes sense chemokines on the endothelial cells, become activated through G-protein signaling, and up-regulate integrins such as very late antigen 4 (VLA-4) (Sasaki et al., 2007; Sasaki et al., 2008a; Sasaki et al., 2008b; Sasaki et al., 2009). Lymphocyte function-associated molecules (LFAs) on lymphocytes allow for a stable interaction to their ligands vascular cell adhesion proteins (VCAMs) and inter-cellular adhesion molecules (ICAMs) on endothelial cells. Finally, with this tight interaction in place, the cells transmigrate into the parenchyma.
2.2. Immunosuppression by gliomas
Previously characterized immunological impairments in glioma patients have included low peripheral lymphocyte counts, reduced delayed-type hypersensitivity reactions to recall antigens, and impaired proliferating responses by peripheral blood mononuclear cells (PBMCs). Gliomas are known to achieve these by producing imunosuppressive molecules and inducing immunosuppressive leukocytes.
2.2.1. Immunosuppressive factors
Transforming growth factor (TGF-)
TGF-β is the most potent immunosuppressive cytokine; its biological effects are multiple and complex (Gorelik et al., 2002). They include the inhibition of 1) APC maturation 2) antigen presentation of APCs, 3) T-cell activation, and 4) their differentiation towards effector cells. Recent studies have shown that TGF-β is up-regulated in glioma cell clones that are resistant to the cytotoxic effects of allogeneic cytotoxic T-cells (CTLs), suggesting the significance of TGF-β in glioma immune escape mechanisms (Gomez et al., 2007; Ueda et al., 2009).
Interleukin 10 (IL-10)
IL-10 is also known to be a strong immunosuppressive cytokine (Moore et al., 2001). Like TGF-β, this cytokine has pleiotropic effects in immunoregulation and inflammation. It down-regulates the expression of Th1 cytokines, MHC class II antigens, and costimulatory molecules on APCs. The expression levels of IL-10 in glioma tissue correlate with glioma grade as well as a degree of brain invasiveness (Huettner et al., 1997; Nitta et al., 1994).
Prostaglandin E2 (PGE2)
PGE2 is a product of arachadonic acid metabolism. It is produced at sites of inflammation or tissue damage where it exerts many effects including the enhancement of vascular permeability. As PGE2 has profound modulatory effects on T-cell activation and gliomas synthesize PGE2, it is associated with the suppressed T-cell function observed in patients with gliomas (Castelli et al., 1989). In addition, we recently demonstrated that PGE2 production from murine gliomas induces accumulation of tumor-associated myeloid cells that promote growth of gliomas (Fujita et al., 2011).
CCL2; macrophage chemoattractive protein 1 (MCP-1)
CCL2, also known as MCP-1, is a chemokine secreted by a variety of glioma cell lines and expressed in glioblastoma multiforme (GBM) (Desbaillets et al., 1994; Takeshima et al., 1994). In addition to its angiogenetic effects (Salcedo et al., 2000), it is associated with recruitment of immunosuppressive leukocytes, such as tumor-associated macrophages and regulatory T cells (Fujita et al., 2010; Fujita et al., 2011; Huang et al., 2007; Jordan et al., 2008).
Fas receptor/ligand
The Fas receptor is a death receptor on the surface of cells that leads to apoptosis. Malignant gliomas express Fas ligand, which induces apoptotic cell death of adjacent immune cells infiltrating into tumors sites (Walker, P. R. et al., 1997). In addition, Fas receptor expressed on glioma cells induces proinflammatory and angiogenic mediators, which in turn protect and support tumors growth (Shinohara et al., 2000).
B7-homologue 1 (B7-H1); programmed death ligand-1 (PD-L1)
The B7 family consists of co-stimulatory molecules that positively and negatively regulate immune responses. Among them, B7-H1, also known as PD-L1, exerts immunosuppressive functions when interacting with its receptor PD-1 (Chen, 2004). Glioma cells express B7-H1, which subsequently inhibits T-cell functions by decreasing cytokine production levels (IFN-, IL-2, and IL-10) and expression levels of the T-cell activation marker CD69 (Wintterle et al., 2003). Glioma cells often exhibit mutations in a tumor-suppressor gene phosphatase and tensin homolog (PTEN), and loss of functions in PTEN also leads to up-regulation of B7-H1 (Parsa et al., 2007).
2.2.2. Immunosuppressive leukocytes
A large number of observations suggest that certain types of immune cells in the tumor micrienvironment (TME) are not innocent bystanders at brain tumor sites, but they actively promote tumor development and progression. Inflammatory cells, primarily macrophage/microglia and regulatory T-cells, may affect these processes via their ability to express a large variety of factors, including immunoregulatory cytokines. These cytokines may be secreted not only by inflammatory cells, but also by the tumor cells and stroma cells, together establishing a network of factors that significantly affects brain tumor.
Macrophages/microglia
In the CNS, macrophage/microglial cells constitute the first line of cellular defense against a variety of stressors, participating in the regulation of innate and adaptive immune responses (Graeber et al., 2002). Resident microglias are CD11b+/CD45dim whereas macrophages are CD11b+/CD45high. Intratumoral macrophage/microglia density is higher than in normal brain and abundance of microglia correlates with the grade of malignancy (Badie et al., 2000).
In contrast, the defense functions of macrophage/microglia against glioma are compromised in the TME. Although these cells express Toll-like receptors (TLRs), critical components for APCs to mediate innate immune responses and activate adaptive immune responses, those in the TME are unable to activate T-cells properly (Hussain et al., 2006). Consistently, macrophages/microglia release many factors, including extracellular matrix proteases (MMPs) and cytokines, which may directly or indirectly influence tumor migration/invasiveness and proliferation (Watters et al., 2005). In addition, glioma cell migration is stimulated by the presence of macrophage/microglia (Bettinger et al., 2002). Taken together, macrophages/microglias in gliomas promote the invasive phenotype of these tumors.
Regulatory T-cells (Treg)
The suppressive activity of Tregs has been implicated as an important factor limiting immune-mediated destruction of tumor cells. The presence of CD4+FoxP3+ Tregs correlates with impairment of T-cell proliferation in peripheral blood specimens in GBM patients (Fecci et al., 2006). Moreover, tumor infiltration by Tregs correlates with tumor grade and prognosis (Heimberger et al., 2008).
CD4+FoxP3+ Tregs in gliomas have been shown to express CD25, CTLA-4, GITR, and CXCR4 at high levels (Grauer et al., 2007). Intratumoral accumulation and activation of CD4+FoxP3+ Treg act as a dominant immune escape mechanism of gliomas and underline the importance of controlling tumor-infiltrating Treg in glioma immunotherapy.
3. Immunotherapy for gliomas
In this section, we will first discuss molecular targets for gliomas. Then, we will discuss two modalities: adoptive T-cell therapy (passive immunotherapy) and glioma vaccine (active immunotherapy).
3.1. Target molecules for gliomas
It is essential to know about potent target molecules for glioma immunotherapy. The following section will discuss selected human glioma-associated antigen (GAA)-derived epitopes that appear to be promising based on relatively restricted expression (compared with the normal brain) as well as well-characterized immunogenicity.
IL-13R2
IL-13Rα2 is a membrane glycoprotein that is overexpressed by >80% of malignant gliomas but is not expressed in normal brain tissues or other normal organs except for testes (Debinski et al., 1999). Therefore, IL-13R2 has attracted significant attention as a target for glioma therapy (Kahlon et al., 2004). We recently found that an analogue peptide of natural IL-13R2345-353, in which the first and ninth amino-acid residues tryptophan and isoleucine have been replaced by valine and alanine, respectively, can elicit a greater CTL response against HLA-A2+ IL-13R2+ glioma cells compared with the natural peptide (IL-13R2345-353:1A9V) (Eguchi et al., 2006).
EphA2
EphA2 is a tyrosine kinase receptor that plays a role in carcinogenesis (Dodelet et al., 2000). We have reported that EphA2883-891 is expressed on gliomas and able to elicit an HLA-A2-restricted CTL response against glioma cell lines (Hatano et al., 2005). Furthermore, EphA2 mRNA overexpression was found to correlate inversely with survival in a panel of 21 GBMs (Liu et al., 2006). These findings support the idea that targeting of EphA2 by immunotherapy may provide a major impact in controlling tumor growth and prolonging patients’ survival.
Survivin
Survivin is an apoptosis inhibitor protein overexpressed in most human cancers including gliomas (Blanc-Brude et al., 2002; Uematsu et al., 2005). Therefore, induction of immune response against Survivin appears to be an attractive strategy. Of interest, high level expression of Survivin was correlated with poor prognosis in patients with grade II or III astrocytomas (Uematsu et al., 2005).
Wilm’s tumor 1 (WT1)
WT1 is a transcription factor oncogene that is overexpressed in various types of leukemia and solid tumor cells (Oka et al., 2002). Inhibition of WT1 in leukemic cell lines led to decrease in proliferation and increase in apoptosis of tumor cells (Glienke et al., 2007). Human gliomas also express WT1 at high levels (Izumoto et al., 2008; Rushing et al., 2010; Schittenhelm et al., 2008). These finding imply that elimination of tumor cells that overexpress WT1 may allow efficient control against glioma growth.
Sry-related high mobility group box (SOX)
SOX is a family of transcriptional cofactors implicated in the control of diverse developmental processes and exhibit highly dynamic expression patterns during development of diverse tissues and cell types, especially during embryogenesis (Wegner, 1999). Indeed, SOX2 (Gangemi et al., 2009), SOX5 (Ueda et al., 2007), SOX6 (Ueda et al., 2004), and SOX11 (Schmitz et al., 2007) are highly expressed in glioma cell lines and a majority of glioma tissues. Their preferential expression in glioma and immunogenicity indicate that SOX proteins are attractive targets for immunotherapy.
Type III variant of the EGFR mutation (EGFRvIII)
EGFRvIII is present in 30-50% of patients with GBM. Despite the limited frequency in gliomas, EGFRvIII and IL-13R2 are expressed most restrictedly in primary glioma tissues compared with normal tissues (Saikali et al., 2007). Therefore, this antigen also appears to be an attractive target for glioma immunotherapy.
Cytomegalovirus (CMV)
Recent reports have demonstrated the presence of the cytomegalovirus (CMV) proteins as well as CMV mRNA in a majority of human GBMs (Barami, 2010; Cobbs et al., 2002; Lucas et al., 2010; Mitchell et al., 2008; Scheurer et al., 2008). Therefore, CMV in gliomas could serve as an immunotherapeutic target for glioma. In addition, the facilitation of an immune response against viral antigens contrasts with the difficulty of immunization against self antigens. It will be intriguing to introduce the CMV-derived epitope to multiepitope-based vaccine for glioma.
3.2. Adoptive T-cell therapy (ACT) for gliomas
ACT involves passive infusion or transfer of autologous CTLs specific for tumor antigens to the host. Although ACT are currently evaluated as experimental therapy for limited types of cancers (Gattinoni et al., 2006; Morgan et al., 2006), this strategy may hold promise as an attractive future immunotherapeutic intervention against gliomas. In particular, based on strong findings that CTLs have the capacity to migrate into brain parenchyma (Ransohoff et al., 2003), the approach has been vastly improved by the use of recent advances in several areas of human T-cell biology including
3.2.1. Source of glioma-reactive CTLs
Peripheral Bloods
PBMCs from glioma patients can be expanded
Glioma tissues
Another important source of the GAA-specific CTLs is a glioma tissue itself. A tumor nodule contains tumor-reactive CTLs that can be first polyclonally expanded
3.2.2. Manipulation of glioma-reactive CTLs ex vivo
Choice of T-cell subtypes
In general, an effector T-cell subset (TE) is predominantly enriched during
Cloning of high-avidity T-cell receptors (TCRs)
Since the majority of GAAs are poorly immunogenic to raise CTLs that possess TCRs with low avidity, a number of modification have been made for ACT. One of attempts is to systematically search tumor-specific CD8+ T-cells for clone(s) with higher TCR avidity, clone TCRα and β genes, and exogenously induce the high-avidity TCR exogenously in bulk CD8+ T-cells. Li
Establishment of chimeric antigen receptors (CARs)
An interesting alternative to expression of high-avidity TCRs on T-cells is to express a chimeric molecule that has antigen-binding domains of a monoclonal antibody fused with a signal transduction domain of CD3 (Gross et al., 1989), namely chimeric antigen receptors (CAR). A significant advantage of CARs over TCRs is that the antigen recognition is not restricted by expression of certain MHC class I molecules. Recently, CARs have been used to treat a number of cancers (Cartellieri et al., 2010). CAR-based approaches are currently being developed for gliomas as well (Kahlon et al., 2004; Ohno et al., 2010).
3.2.3. Current attempts of ACT for gliomas
There have been a number of clinical trials for malignant gliomas using ACT (Table1) (Vauleon et al., 2010). Among them, three Phase I trials (Holladay et al., 1996; Plautz et al., 1998; Wood et al., 2000) and two pilot studies (Plautz et al., 2000; Sloan et al., 2000) used CTLs obtained from lymph nodes or PBMCs after intradermal vaccination. Holladay
Type of trials | Immune responses | Clinical responses | ||
Holladay et al., 1996 | Phase I | N = 15 recurrent HGG 12 GBM, 3 AA | DTH (15/15) | No PR or SD Median FPS: ≥8 mo |
Plautz et al., 1998) | Phase I | N = 10 recurrent HGG 9 GBM, 1 AA | 3 PR Median FPS: "/> 12 mo | |
Plautz et al., 2000 | Pilot study | N =9 recurrent HGG 6 GBM, 3 Gr3 | DTH (9/9) | 3 PR |
Wood et al., 2000 | Phase I | N =12 newly diagnosed glioma 6 GBM, 2 Gr2, 4 Gr3 | DTH (12/12) | 4 PR, 2 SD |
Sloan et al.,2000 | Pilot study | N =19 recurrent HGG 16 GBM, 2 AA, 1 gliosarcoma | DTH (17/19) | 1 CR, 7 PR, 9 SD Median OS : 12 mo |
3.3. Glioma vaccines
In addition to the ACT strategy described above, we will discuss glioma vaccine strategies in this section. They include 1) whole glioma cell vaccines, 2) peptide-based vaccines targeting glioma-associated antigens, and 3) DC vaccines.
3.3.1. Whole glioma cell vaccines
Initial vaccination strategies for gliomas consisted of subcutaneous inoculations of irradiated, autologous (Wikstrand et al., 1980) or allogeneic (Zhang et al., 2007) glioma cells. This type of vaccine has the advantage of providing a panel of multiple potential GAAs that are naturally expressed by glioma cells. Especially, autologous glioma cells should allow immunizations against the most relevant GAAs expressed in the patient’s tumor (i.e. tailored medicine). Potential downsides of this approach, however, include: 1) cumbersome procedures and quality control (QC)/quality assurance (QA) issues associated with large scale cultures of autologous glioma cells and 2) theoretical risks of autoimmune encephalomyelitis (Wikstrand et al., 1980). Nevertheless, this type of vaccine strategy has been carefully examined (Table 2). Schneider et al. (Schneider et al., 2001) and Steiner et al.(Steiner et al., 2004) reported pilot clinical trials using autologous glioma cells modified
Type of trials | Immune responses | Clinical responses | |||
Schneider et al., 2001 | Pilot study | N =11 newly diagnosed GBM | infected with NDV, inactivated with cisplatinum | DTH (11/11) T cell infiltrate (4/4) | No survival benefit |
Andrews et al., 2001 | Pilot study | N =12 8 GBM, 4 AA | IGF-RA/AS ODN | T cell infiltrate (4/9) | 2 CR, 4 PR, 2 SD |
Steiner et al., 2004 | Pilot study | N =23 GBM | infected with NDV | DTH (15/15) ELISPOT (3/3) T cell infiltrate (6/7) | 1 CR Median OS: 100 wks |
Parney et al., 2006 | Pilot study | N =6 3 recurrent GBM 3 melanoma | transduced with B7-2 and GM-CSF | No CTL activity | Longer PFS (3/6 GBM) |
Ishikawa et al., 2007 | Pilot study | N =12 8 newly diagnosed GBM, 4 recurrent GBM | formalin-fixed | DTH (9/12) | 1 CR, 1 PR,2 MR Median OS:10.7 mo |
Clavreul et al., 2010 | Phase I | N =5 recurrent HGG 4 GBM, 1 AOA | irradiated | DTH (2/5) | 3 SD |
with Newcastle-Disease-Virus (NDV), which is known to serve as an vaccine adjuvant and therefore to improve the efficacy of glioma vaccines. Recently, Ishikawa
3.3.2. Peptide-based vaccines targeting glioma-associated antigens
In vaccines using synthetic peptides for shared GAA-epitopes, advantages and disadvantages are distinct from those in whole glioma cell approaches. While synthetic GAA peptide-based vaccines may not adequately target antigens in each patient’s tumor, these vaccines have less concern for autoimmunity and provide “off the shelf” feasibility. Indeed, a wide range of peptide-based vaccines have been clinically evaluated (Table 3). Yajima
Type of trials | Immune responses | Clinical responses | |||
Yajima et al., 2005 | Phase I | N = 25 17 GBM, 8 Gr3 | multiple | DTH (11/21) CTL activity (14/21) | 5 PR, 8 SD Median OS: 89 wks |
Izumoto et al., 2008 | Phase II | N = 21 recurrent GBM | WT1 | DTH (21/21) | 2 PR, 10 SD Median PFS: 20 wks |
Sampson et al., 2010 | Phase II | N = 18 newly diagnosed GBM | EGFRvIII | DTH (5/9) CTL activity (10/12) | Median PFS: 14.2 months Median OS: 26.0 mo |
Terasaki et al., 2011 | Phase I | N = 12, recurrent GBM | multiple | CTL activity (8/12) | 1 PR, 7 SD Median PFS: 2.3 mo Median OS: 18.9 mo |
3.3.3. DC vaccines
DCs are the most potent antigen-presenting cells, driving the activation of T-cells in response to invading microorganisms (Banchereau et al., 2000). The availability to culture DCs from human peripheral blood monocytes has generated significant interest in using DCs in novel cancer vaccination strategies (Banchereau et al., 2000).
To induce tumor-specific immune reaction via DCs, antigen elusion from tumor cells has been performed (Table 4). Yu
Type of trials | Immune responses | Clinical responses | ||
Yu et al.,2001 | Phase I | N = 9 newly diagnosed HGG 7 GBM, 2 AA | CTL activity (4/7) T cell infiltrate (2/4) | Median OS: 455 d |
Wheeler et al., 2004 | Phase I/II | N = 25 newly diagnosed GBM | CTL activity (8/24) | 3 PR |
Liau et al., 2005 | Phase I | N = 12 GBM 5 recurrent 7 newly diagnosed | CTL activity (6/12) T cell infiltrate (4/8) | 1 PR Median OS: 23.4 mo |
However, pulsing DCs with eluted peptides requires a large culture of autologous glioma cells and time-consuming procedures, for which QC/QA is not always feasible. To overcome this issue, glioma cell lysate has been used to pulse DCs in a number of trials (Table 5). Yamanaka
Type of trials | Immune responses | Clinical responses | ||
Yamanakaet al., 2003 | Phase I/II | N = 10 7 GBM, 3 recurrent Gr3 | DTH (3/6) ELISPOT (2/5) T cell infiltrate (2/2) | 2 MR, 4 SD Median OS: "/> 200 wks |
Yu et al.,2004 | Phase I | N = 14 1 GBM, 1 AA, 9 recurrent GBM, 3 recurrent AA | CTL activity (4/9) T cell infiltrate (3/6) | Median OS: 133 wks |
Rutkowskiet al., 2004 | Phase I | N = 12 recurrent HGG 11 GBM, 1 others | DTH (7/8) | 2 CR, 1 PR, 1 SD Median OS: 10.5 mo |
Yamanakaet al., 2005 | Phase I/II | N = 24 recurrent HGG 18 GBM, 6 Gr3 | DTH (8/17) ELISPOT (7/16) | 1PR, 3MR, 10 SD Median OS: 480 d Longer survival if DC maturation or IC injection |
Okada, H.et al., 2007 | Phase I | N = 5 newly diagnosed GBM | No response | No response |
Wheeler et al., 2008 | Phase II | N = 34 GBM 23 recurrent 11 newly diagnosed | ELISPOT (17/34) | 3 CR, 1 PR Median OS: 642 d |
De Vleeschouwer et al., 2004 | Phase I/II | N = 56 recurrent GBM | DTH (11/ 23) | Median OS: 9.6 mo |
Walker, D. G. et al., 2008 | Phase I | N = 13 9 GBM, 4 AA | T cell infiltrate (3/3) | 2 CR, 3 PR |
Ardon et al., 2010 | Phase I/II | N = 8 newly diagnosed GBM | DTH (2/5) ELISPOT (5/8) | Median OS: 24 mo |
Prins et al., 2011 | Phase I | N = 23 GBM 8 recurrent 15 newly diagnosed | increase in systemic TNF-α and IL-6 | Median OS: 31.4 mo |
While these studies demonstrate early success of DC-based vaccines in glioma patients, based on our preclinical data demonstrating that type-1 CTLs are capable of mediating effective anti-CNS tumor immunity (Fujita et al., 2008; Nishimura et al., 2006), we recently completed a Phase I/II study of vaccines evaluating safety and immunological activities of vaccines using -type-1-polarized DCs (DC1) that are able to produce high levels of IL-12 and induce long-lived type-1 T-cell responses (Okada, H. et al., 2011). In this study, patients with recurrent malignant glioma received intra-lymphnodal injection of αDC1 loaded with synthetic peptides for GAA epitopes and administration of polyinosinic-polycytidylic acid [poly(I:C)] stabilized by lysine and carboxymethylcellulose (poly-ICLC) in HLA-A2+ patients with recurrent malignant gliomas. GAAs for these peptides are EphA2, IL-13R-α2, YKL-40, and gp100. The regimen was well-tolerated and induced positive immune responses against at least one of the vaccination-targeted GAAs in peripheral blood mononuclear cells in 58% of patients. Peripheral blood samples demonstrated significant up-regulation of type 1 cytokines and chemokines, including interferon-α and CXCL10. For at least 12 months, nine patients achieved progression-free status. One patient with recurrent GBM demonstrated a sustained complete response. IL-12 production levels by αDC1 positively correlated with time to progression. These data support safety, immunogenicity, and preliminary clinical activity of poly-ICLC-boosted αDC1-based vaccines and warrant further development of this approach. Although these Phase I/II studies demonstrate preliminary clinical efficacy, the ultimate judgment for clinical activity has to be made by rigorous evaluation in randomized studies.
Type of trials | Antigen Source | Immune responses | Clinical responses | ||
Kikuchi et al., 2001 | Phase I | N =8 5 GBM, 2 AA, 1 AO | Fused tumor cells | ELISPOT (6/6) | 1 MR, 6 SD |
Caruso et al., 2004 | Phase I | N =7 recurrent tumors 2 GBM, 1 AA, 4 others | tumor RNA | No PBMC respnse | 1 PR, 4 SD |
Kikuchi et al., 2004 | Phase I | N =15 recurrent HGG 6 GBM, 7 AA, 2 OAA | Fused tumor cells | DTH (15/15) CTL activity (2/8) | 4 PR, 2 SD, 1 MR |
Sampsonet al., 2009 | Phase I | N =12 newly diagnosed GBM | EGFRvIII | DTH (5/9) CTL activity (10/12) | Median OS: 22.8 mo |
Okada, H.et al., 2011 | Phase I/II | N = 22 13 GBM, 5 AA, 3 AO, 1 AOA | EphA2, IL-13R-α2, YKL-40, gp100 | ELISPOT (10/22) increase in systemic Th1 cytokines | Median PFS: 4 mo (GBM) 13 mo (AG) |
4. Conclusion
We reviewed recent progress in the field of brain and brain tumor immunology. We also reported recent progress and current challenges in immunotherapeutic strategies for brain tumors. It is clear that the CNS and gliomas are equipped with numerous and layered immunosuppressive and immune escape mechanisms, perhaps including ones that we have not yet identified. These discoveries, however, allow us to develop strategies to overcome each of these mechanisms.
Remaining unique challenges against gliomas include relative difficulties in obtaining tumor tissues following immunotherapeutic treatments. Unlike other cancers, intracranial glioma tissues are not readily accessible following vaccine treatment. Designing neo-adjuvant settings with vaccines is not always feasible because recurrent malignant gliomas, for which surgical resection is clinically indicated, typically do not allow us to wait for weeks before surgery and often require treatment with high dose corticosteroids.
As reviewed in this article, the concept of immunotherapy has a diverse scope of strategies and target molecules. Extensive review of each field in this article has led us to identify the challenge for each strategy. Such challenges, however, may be overcome by appropriate combinations with other strategies. For example, ACT strategies may need to be combined with appropriate adjuvants and/or vaccinations to promote long lasting memory responses and anti-tumor immunosurveillance. However, when each of these agents is owned by separate industries with intellectual properties, such creative combinatorial strategies may not be implemented as efficiently as we would wish. Although several early phase clinical trials demonstrated promising therapeutic outcomes to date, clinical trials of immunotherapy for gliomas have not yet demonstrated objective proof of clinical efficacy in randomized studies. The eventual success of immunotherapies for brain tumors will be dependent upon not only an in-depth understanding of immunology behind the brain and brain tumors, but also the implementation of molecularly targeted trials that address multiple layers of challenges in brain tumors.
Acknowledgments
Financial Support: the National Institute of Health 2R01NS055140, 2P01NS40923, 1P01CA132714, P3CA047904.
References
- 1.
Abbott N. J. Ronnback L. Hansson E. 2006 Astrocyte-endothelial interactions at the blood-brain barrier,,7 1 January 2006),41 53 0147-1003 X - 2.
Aloisi F. 2001 Immune function of microglia,,36 2 November 2001),165 179 0894-1491 - 3.
Andrews D. W. Resnicoff M. Flanders A. E. Kenyon L. Curtis M. Merli G. Baserga R. Iliakis G. Aiken R. D. 2001 Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas,,19 8 April 2001),2189 2200 0073-2183 X - 4.
Ardon H. Van Gool S. Lopes I. S. Maes W. Sciot R. Wilms G. Demaerel P. Bijttebier P. Claes L. Goffin J. Van Calenbergh F. De Vleeschouwer S. 2010 Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study,,99 2 September 2010),261 272 0016-7594 X - 5.
Badie B. Schartner J. M. 2000 Flow cytometric characterization of tumor-associated macrophages in experimental gliomas,,46 4 April 2000),957 961 discussion 961-952,0014-8396 X - 6.
Banchereau J. Briere F. Caux C. Davoust J. Lebecque S. Liu Y. J. Pulendran B. Palucka K. 2000 Immunobiology of dendritic cells,,18 June 2000),767 811 0732-0582 - 7.
Barami K. 2010 Oncomodulatory mechanisms of human cytomegalovirus in gliomas,,17 7 July 2010),819 823 0967-5868 - 8.
Bettinger I. Thanos S. Paulus W. 2002 Microglia promote glioma migration,,103 4 April 2002),351 355 0001-6322 - 9.
Blanc-Brude O. P. Yu J. Simosa H. Conte M. S. Sessa W. C. Altieri D. C. 2002 Inhibitor of apoptosis protein survivin regulates vascular injury,,8 9 September 2002),987 994 1078-8956 - 10.
Cartellieri M. Bachmann M. Feldmann A. Bippes C. Stamova S. Wehner R. Temme A. Schmitz M. 2010 Chimeric antigen receptor-engineered T cells for immunotherapy of cancer,,2010 May 2010),956304 1110-7243 - 11.
Caruso D. A. Orme L. M. Neale A. M. Radcliff F. J. Amor G. M. Maixner W. Downie P. Hassall T. E. Tang M. L. Ashley D. M. 2004 Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer,,6 3 July 2004),236 246 1522-8517 - 12.
Castelli M. G. Chiabrando C. Fanelli R. Martelli L. Butti G. Gaetani P. Paoletti P. 1989 Prostaglandin and thromboxane synthesis by human intracranial tumors,,49 6 March 1989),1505 1508 0008-5472 - 13.
Chen L. 2004 Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity,,4 5 May 2004),336 347 1474-1733 - 14.
Clavreul A. Piard N. Tanguy J. Y. Gamelin E. Rousselet M. C. Leynia P. Menei P. 2010 Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas,,17 7 July 2010),842 848 0967-5868 - 15.
Cobbs C. S. Harkins L. Samanta M. Gillespie G. Y. Bharara S. King P. H. Nabors L. B. Cobbs C. G. Britt W. J. 2002 Human cytomegalovirus infection and expression in human malignant glioma,,62 12 June 2002),3347 3350 0008-5472 - 16.
De Vleeschouwer S. Van Calenbergh F. Demaerel P. Flamen P. Rutkowski S. Kaempgen E. Wolff J. E. Plets C. Sciot R. Van Gool S. W. 2004 Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report,,100 5 May 2004),492 497 0022-3085 - 17.
de Vos A. F. van Meurs M. Brok H. P. Boven L. A. Hintzen R. Q. van der Valk P. Ravid R. Rensing S. Boon L. Hart t. B. A. Laman J. D. 2002 Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs,,169 10 November 2002),5415 5423 0022-1767 - 18.
Debinski W. Gibo D. M. Hulet S. W. Connor J. R. Gillespie G. Y. 1999 Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas,,5 5 May 1999),985 990 1078-0432 - 19.
Desbaillets I. Tada M. de Tribolet N. Diserens A. C. Hamou M. F. Van Meir E. G. 1994 Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro,,58 2 July 1994),240 247 0020-7136 - 20.
Dodelet V. C. Pasquale E. B. 2000 Eph receptors and ephrin ligands: embryogenesis to tumorigenesis,,19 49 November 2000),5614 5619 0950-9232 - 21.
Dreno B. Nguyen J. M. Khammari A. Pandolfino M. C. Tessier M. H. Bercegeay S. Cassidanius A. Lemarre P. Billaudel S. Labarriere N. Jotereau F. 2002 Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma,,51 10 November 2002),539 546 0340-7004 - 22.
Dudley M. E. Wunderlich J. R. Yang J. C. Sherry R. M. Topalian S. L. Restifo N. P. Royal R. E. Kammula U. White D. E. Mavroukakis S. A. Rogers L. J. Gracia G. J. Jones S. A. Mangiameli D. P. Pelletier M. M. Gea-Banacloche J. Robinson M. R. Berman D. M. Filie A. C. Abati A. Rosenberg S. A. 2005 Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma,,23 10 April 2005),2346 2357 0073-2183 X - 23.
Dunn G. P. Dunn I. F. Curry W. T. 2007 Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma,,7 August 2007),12 1424-9634 - 24.
Eguchi J. Hatano M. Nishimura F. Zhu X. Dusak J. E. Sato H. Pollack I. F. Storkus W. J. Okada H. 2006 Identification of interleukin-13 receptor 2 peptide analogues capable of inducing improved antiglioma CTL responses,,66 11 June 2006),5883 5891 0008-5472 - 25.
Engelhardt B. 2008 The blood-central nervous system barriers actively control immune cell entry into the central nervous system,,14 16 August 2008),1555 1565 1381-6128 - 26.
Fecci P. E. Mitchell D. A. Whitesides J. F. Xie W. Friedman A. H. Archer G. E. Herndon J. E. 2nd Bigner D. D. Dranoff G. Sampson J. H. 2006 Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma,,66 6 March 2006),3294 3302 0008-5472 - 27.
Fujita M. Zhu X. Sasaki K. Ueda R. Low K. L. Pollack I. F. Okada H. 2008 Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma,,180 4 February 2008),2089 2098 0022-1767 - 28.
Fujita M. Zhu X. Ueda R. Sasaki K. Kohanbash G. Kastenhuber E. R. Mc Donald H. A. Gibson G. A. Watkins S. C. Muthuswamy R. Kalinski P. Okada H. 2009 Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells-significant roles of CXCL10,,69 4 February 2009),1587 1595 0008-5472 - 29.
Fujita M. Scheurer M. E. Decker S. A. Mc Donald H. A. Kohanbash G. Kastenhuber E. R. Kato H. Bondy M. L. Ohlfest J. R. Okada H. 2010 Role of type 1 IFNs in antiglioma immunosurveillance-using mouse studies to guide examination of novel prognostic markers in humans,,16 13 July 2010),3409 3419 1078-0432 - 30.
Fujita M. Kohanbash G. Fellows-Mayle W. Hamilton R. L. Komohara Y. Decker S. A. Ohlfest J. R. Okada H. 2011 COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells,,71 7 April 2011),2664 2667 0008-5472 - 31.
Gangemi R. M. Griffero F. Marubbi D. Perera M. Capra M. C. Malatesta P. Ravetti G. L. Zona G. L. Daga A. Corte G. 2009 SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity,,27 1 January 2009),40 48 1066-5099 - 32.
Gattinoni L. Powell D. J. Jr Rosenberg S. A. Restifo N. P. 2006 Adoptive immunotherapy for cancer: building on success,,6 5 May 2006),383 393 1474-1733 - 33.
Glienke W. Maute L. Koehl U. Esser R. Milz E. Bergmann L. 2007 Effective treatment of leukemic cell lines with wt1 siRNA,,21 10 October 2007),2164 2170 0887-6924 - 34.
Gomez G. G. Kruse C. A. 2007 Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-β,,30 3 April 2007),261 273 1524-9557 - 35.
Gorelik L. Flavell R. A. 2002 Transforming growth factor-beta in T-cell biology,,2 1 January 2002),46 53 1474-1733 - 36.
Graeber M. B. Scheithauer B. W. Kreutzberg G. W. 2002 Microglia in brain tumors,,40 2 November 2002),252 259 0894-1491 - 37.
Grauer O. M. Nierkens S. Bennink E. Toonen L. W. Boon L. Wesseling P. Sutmuller R. P. Adema G. J. 2007 CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo,,121 1 July 2007),95 105 0020-7136 - 38.
Gross G. Waks T. Eshhar Z. 1989 Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity,,86 24 December 1989),10024 10028 0027-8424 - 39.
Hatano M. Eguchi J. Tatsumi T. Kuwashima N. Dusak J. E. Kinch M. S. Pollack I. F. Hamilton R. L. Storkus W. J. Okada H. 2005 EphA2 as a glioma-associated antigen: a novel target for glioma vaccines,,7 8 August 2005),717 722 1522-8002 - 40.
Heimberger A. B. Abou-Ghazal M. Reina-Ortiz C. Yang D. S. Sun W. Qiao W. Hiraoka N. Fuller G. N. 2008 Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas,,14 16 August 2008),5166 5172 1078-0432 - 41.
Holladay F. P. Heitz-Turner T. Bayer W. L. Wood G. W. 1996 Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma,,27 2 February 1996),179 189 0016-7594 X - 42.
Huang B. Lei Z. Zhao J. Gong W. Liu J. Chen Z. Liu Y. Li D. Yuan Y. Zhang G. M. Feng Z. H. 2007 CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers,,252 1 July 2007),86 92 0304-3835 - 43.
Huettner C. Czub S. Kerkau S. Roggendorf W. Tonn J. C. 1997 Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro,,17 5A September 1997),3217 3224 0250-7005 - 44.
Hussain S. F. Yang D. Suki D. Aldape K. Grimm E. Heimberger A. B. 2006 The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses,,8 3 July 2006),261 279 1522-8517 - 45.
Ishikawa E. Tsuboi K. Yamamoto T. Muroi A. Takano S. Enomoto T. Matsumura A. Ohno T. 2007 Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients,,98 8 August 2007),1226 1233 1347-9032 - 46.
Izumoto S. Tsuboi A. Oka Y. Suzuki T. Hashiba T. Kagawa N. Hashimoto N. Maruno M. Elisseeva O. A. Shirakata T. Kawakami M. Oji Y. Nishida S. Ohno S. Kawase I. Hatazawa J. Nakatsuka S. Aozasa K. Morita S. Sakamoto J. Sugiyama H. Yoshimine T. 2008 Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme,,108 5 May 2008),963 971 0022-3085 - 47.
Jordan J. T. Sun W. Hussain S. F. De Angulo G. Prabhu S. S. Heimberger A. B. 2008 Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy,,57 1 January 2008),123 131 0340-7004 - 48.
Kahlon K. S. Brown C. Cooper L. J. Raubitschek A. Forman S. J. Jensen M. C. 2004 Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells,,64 24 December 2004),9160 9166 0008-5472 - 49.
Kantoff P. W. Higano C. S. Shore N. D. Berger E. R. Small E. J. Penson D. F. Redfern C. H. Ferrari A. C. Dreicer R. Sims R. B. Xu Y. Frohlich M. W. Schellhammer P. F. 2010 Sipuleucel-T immunotherapy for castration-resistant prostate cancer,,363 5 July 2010),411 422 1533-4406 - 50.
Kikuchi T. Akasaki Y. Irie M. Homma S. Abe T. Ohno T. 2001 Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells,,50 7 September 2001),337 344 0340-7004 - 51.
Kikuchi T. Akasaki Y. Abe T. Fukuda T. Saotome H. Ryan J. L. Kufe D. W. Ohno T. 2004 Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12,,27 6 November 2004),452 459 1524-9557 - 52.
Kuwashima N. Nishimura F. Eguchi J. Sato H. Hatano M. Tsugawa T. Sakaida T. Dusak J. E. Fellows-Mayle W. K. Papworth G. D. Watkins S. C. Gambotto A. Pollack I. F. Storkus W. J. Okada H. 2005 Delivery of dendritic cells engineered to secrete IFN- into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways,,175 4 August 2005),2730 2740 0022-1767 - 53.
Li Y. Moysey R. Molloy P. E. Vuidepot A. L. Mahon T. Baston E. Dunn S. Liddy N. Jacob J. Jakobsen B. K. Boulter J. M. 2005 Directed evolution of human T-cell receptors with picomolar affinities by phage display,,23 3 March 2005),349 354 1087-0156 - 54.
Liau L. M. Prins R. M. Kiertscher S. M. Odesa S. K. Kremen T. J. Giovannone A. J. Lin J. W. Chute D. J. Mischel P. S. Cloughesy T. F. Roth M. D. 2005 Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment,,11 15 August 2005),5515 5525 1078-0432 - 55.
Liu F. Park P. J. Lai W. Maher E. Chakravarti A. Durso L. Jiang X. Yu Y. Brosius A. Thomas M. Chin L. Brennan C. De Pinho R. A. Kohane I. Carroll R. S. Black P. M. Johnson M. D. 2006 A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma,,66 22 November 2006),10815 10823 0008-5472 - 56.
Lucas K. G. Bao L. Bruggeman R. Dunham K. Specht C. 2010 The detection of CMV65 and IE1 in glioblastoma multiforme,,103 2 September 2010), pp. 231-238,0016-7594 X - 57.
Mitchell D. A. Xie W. Schmittling R. Learn C. Friedman A. Mc Lendon R. E. Sampson J. H. 2008 Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma,,10 1 February 2008),10 18 1522-8517 - 58.
Moore K. W. de Waal Malefyt. R. Coffman R. L. O’Garra A. 2001 Interleukin-10 and the interleukin-10 receptor,,19 March 2001),683 765 0732-0582 - 59.
Morgan R. A. Dudley M. E. Wunderlich J. R. Hughes M. S. Yang J. C. Sherry R. M. Royal R. E. Topalian S. L. Kammula U. S. Restifo N. P. Zheng Z. Nahvi A. de Vries C. R. Rogers-Freezer L. J. Mavroukakis S. A. Rosenberg S. A. 2006 Cancer regression in patients after transfer of genetically engineered lymphocytes,,314 5796 October 2006),126 129 0036-8075 - 60.
Nishimura F. Dusak J. E. Eguchi J. Zhu X. Gambotto A. Storkus W. J. Okada H. 2006 Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10,,66 8 April 2006),4478 4487 0008-5472 - 61.
Nitta T. Hishii M. Sato K. Okumura K. 1994 Selective expression of interleukin-10 gene within glioblastoma multiforme,,649 1-2 June 1994),122 128 0006-8993 - 62.
Ohno M. Natsume A. Ichiro Iwami. K. Iwamizu H. Noritake K. Ito D. Toi Y. Ito M. Motomura K. Yoshida J. Yoshikawa K. Wakabayashi T. 2010 Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen,,101 12 December 2010),2518 2524 1347-9032 - 63.
Oka Y. Tsuboi A. Elisseeva O. A. Udaka K. Sugiyama H. 2002 WT1 as a novel target antigen for cancer immunotherapy,,2 1 March 2002),45 54 1568-0096 - 64.
Okada H. Lieberman F. S. Walter K. A. Lunsford L. D. Kondziolka D. S. Bejjani G. K. Hamilton R. L. Torres-Trejo A. Kalinski P. Cai Q. Mabold J. L. Edington H. D. Butterfield L. H. Whiteside T. L. Potter D. M. Schold S. C. Jr Pollack I. F. 2007 Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas,,5 December 2007),67 1479-5876 - 65.
Okada H. Kohanbash G. Zhu X. Kastenhuber E. R. Hoji A. Ueda R. Fujita M. 2009 Immunotherapeutic approaches for glioma,,29 1 April 2009),1 42 1040-8401 - 66.
Okada H. Kalinski P. Ueda R. Hoji A. Kohanbash G. Donegan T. E. Mintz A. H. Engh J. A. Bartlett D. L. Brown C. K. Zeh H. Holtzman M. P. Reinhart T. A. Whiteside T. L. Butterfield L. H. Hamilton R. L. Potter D. M. Pollack I. F. Salazar A. M. Lieberman F. S. 2011 Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with -type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma,,29 3 January 2011),330 336 0073-2183 X - 67.
Okada N. Mori N. Koretomo R. Okada Y. Nakayama T. Yoshie O. Mizuguchi H. Hayakawa T. Nakagawa S. Mayumi T. Fujita T. Yamamoto A. 2005 Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction,,12 2 January 2005),129 139 0969-7128 - 68.
Parney I. F. Chang L. J. Farr-Jones M. A. Hao C. Smylie M. Petruk K. C. 2006 Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas,,78 1 May 2006),71 80 0016-7594 X - 69.
Parsa A. T. Waldron J. S. Panner A. Crane C. A. Parney I. F. Barry J. J. Cachola K. E. Murray J. C. Tihan T. Jensen M. C. Mischel P. S. Stokoe D. Pieper R. O. 2007 Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma,,13 1 January 2007),84 88 1078-8956 - 70.
Perret R. Ronchese F. 2008 Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours?,,72 3 September 2008),187 194 0001-2815 - 71.
Plautz G. E. Barnett G. H. Miller D. W. Cohen B. H. Prayson R. A. Krauss J. C. Luciano M. Kangisser D. B. Shu S. 1998 Systemic T cell adoptive immunotherapy of malignant gliomas,,89 1 July 1998),42 51 0022-3085 - 72.
Plautz G. E. Miller D. W. Barnett G. H. Stevens G. H. Maffett S. Kim J. Cohen P. A. Shu S. 2000 T cell adoptive immunotherapy of newly diagnosed gliomas,,6 6 June 2000),2209 2218 1078-0432 - 73.
Prins R. M. Soto H. Konkankit V. Odesa S. K. Eskin A. Yong W. H. Nelson S. F. Liau L. M. 2011 Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy,,17 6 March 2011),1603 1615 1078-0432 - 74.
Ransohoff R. M. Kivisakk P. Kidd G. 2003 Three or more routes for leukocyte migration into the central nervous system,,3 7 July 2003),569 581 1474-1733 - 75.
Robbins P. F. Dudley M. E. Wunderlich J. El -Gamil M. Li Y. F. Zhou J. Huang J. Powell D. J. Jr Rosenberg S. A. 2004 Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy,,173 12 December 2004),7125 7130 0022-1767 - 76.
Rosenberg S. A. 2008 Overcoming obstacles to the effective immunotherapy of human cancer,,105 35 September 2008),12643 12644 0027-8424 - 77.
Rushing E. J. Sandberg G. D. Horkayne-Szakaly I. 2010 High-grade astrocytomas show increased Nestin and Wilms’s tumor gene (WT1) protein expression,,18 4 August 2010),255 259 1066-8969 - 78.
Rutkowski S. De Vleeschouwer S. Kaempgen E. Wolff J. E. Kuhl J. Demaerel P. Warmuth-Metz M. Flamen P. Van Calenbergh F. Plets C. Sorensen N. Opitz A. Van Gool S. W. 2004 Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study,,91 9 November 2004),1656 1662 0007-0920 - 79.
Saikali S. Avril T. Collet B. Hamlat A. Bansard J. Y. Drenou B. Guegan Y. Quillien V. 2007 Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13R2, gp100 and TRP-2 for immunotherapy,,81 2 January 2007),139 148 0016-7594 X - 80.
Salcedo R. Ponce M. L. Young H. A. Wasserman K. Ward J. M. Kleinman H. K. Oppenheim J. J. Murphy W. J. 2000 Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression,,96 1 July 2000),34 40 0006-4971 - 81.
Sampson J. H. Archer G. E. Mitchell D. A. Heimberger A. B. Herndon J. E. 2nd Lally-Goss D. Mc Gehee-Norman S. Paolino A. Reardon D. A. Friedman A. H. Friedman H. S. Bigner D. D. 2009 An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme,,8 10 October 2009),2773 2779 1535-7163 - 82.
Sampson J. H. Heimberger A. B. Archer G. E. Aldape K. D. Friedman A. H. Friedman H. S. Gilbert M. R. Herndon J. E. 2nd Mc Lendon R. E. Mitchell D. A. Reardon D. A. Sawaya R. Schmittling R. J. Shi W. Vredenburgh J. J. Bigner D. D. 2010 Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma,,28 31 November 2010),4722 4729 0073-2183 X - 83.
Sasaki K. Zhu X. Vasquez C. Nishimura F. Dusak J. E. Huang J. Fujita M. Wesa A. Potter D. M. Walker P. R. Storkus W. J. Okada H. 2007 Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors,,67 13 July 2007),6451 6458 0008-5472 - 84.
Sasaki K. Pardee A. D. Okada H. Storkus W. J. 2008a IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit,,38 10 October 2008),2865 2873 0014-2980 - 85.
Sasaki K. Zhao X. Pardee A. D. Ueda R. Fujita M. Sehra S. Kaplan M. H. Kane L. P. Okada H. Storkus W. J. 2008b Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo,,181 1 July 2008),104 108 0022-1767 - 86.
Sasaki K. Pardee A. D. Qu Y. Zhao X. Ueda R. Kohanbash G. Bailey L. M. Okada H. Muthuswamy R. Kalinski P. Basse P. H. Falo L. D. Storkus W. J. 2009 IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors,,32 8 October 2009),793 802 1524-9557 - 87.
Scheurer M. E. Bondy M. L. Aldape K. D. Albrecht T. El -Zein R. 2008 Detection of human cytomegalovirus in different histological types of gliomas,,116 1 July 2008),79 86 0001-6322 - 88.
Schittenhelm J. Mittelbronn M. Nguyen T. D. Meyermann R. Beschorner R. 2008 WT1 expression distinguishes astrocytic tumor cells from normal and reactive astrocytes,,18 3 July 2008),344 353 1015-6305 - 89.
Schmitz M. Wehner R. Stevanovic S. Kiessling A. Rieger M. A. Temme A. Bachmann M. Rieber E. P. Weigle B. 2007 Identification of a naturally processed T cell epitope derived from the glioma-associated protein SOX11,,245 1-2 January 2007),331 336 0304-3835 - 90.
Schneider T. Gerhards R. Kirches E. Firsching R. 2001 Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme,,53 1 May 2001),39 46 0016-7594 X - 91.
Shinohara H. Yagita H. Ikawa Y. Oyaizu N. 2000 Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation,,60 6 March 2000),1766 1772 0008-5472 - 92.
Sloan A. E. Dansey R. Zamorano L. Barger G. Hamm C. Diaz F. Baynes R. Wood G. 2000 Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes,,9 6 July 2000),e9 1092-0684 - 93.
Steiner H. H. Bonsanto M. M. Beckhove P. Brysch M. Geletneky K. Ahmadi R. Schuele-Freyer R. Kremer P. Ranaie G. Matejic D. Bauer H. Kiessling M. Kunze S. Schirrmacher V. Herold-Mende C. 2004 Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit,,22 21 November 2004),4272 4281 0073-2183 X - 94.
Takeshima H. Kuratsu J. Takeya M. Yoshimura T. Ushio Y. 1994 Expression and localization of messenger RNA and protein for monocyte chemoattractant protein-1 in human malignant glioma,,80 6 June 1994),1056 1062 0022-3085 - 95.
Terasaki M. Shibui S. Narita Y. Fujimaki T. Aoki T. Kajiwara K. Sawamura Y. Kurisu K. Mineta T. Yamada A. Itoh K. 2011 Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen-A24 with recurrent or progressive glioblastoma multiforme,,29 3 January 2011),337 344 0073-2183 X - 96.
Ueda R. Iizuka Y. Yoshida K. Kawase T. Kawakami Y. Toda M. 2004 Identification of a human glioma antigen, SOX6, recognized by patients’ sera,,23 7 February 2004),1420 1427 0950-9232 - 97.
Ueda R. Yoshida K. Kawase T. Kawakami Y. Toda M. 2007 Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients,,120 8 April 2007),1704 1711 0020-7136 - 98.
Ueda R. Fujita M. Zhu X. Sasaki K. Kastenhuber E. R. Kohanbash G. Mc Donald H. A. Harper J. Lonning S. Okada H. 2009 Systemic inhibition of transforming growth factor-β in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines,,15 21 November 2009),6551 6559 1078-0432 - 99.
Uematsu M. Ohsawa I. Aokage T. Nishimaki K. Matsumoto K. Takahashi H. Asoh S. Teramoto A. Ohta S. 2005 Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index,,72 3 May 2005),231 238 0016-7594 X - 100.
Vanderlugt C. L. Miller S. D. 2002 Epitope spreading in immune-mediated diseases: implications for immunotherapy,,2 2 February 2002),85 95 1474-1733 - 101.
Vauleon E. Avril T. Collet B. Mosser J. Quillien V. 2010 Overview of cellular immunotherapy for patients with glioblastoma,,2010 October 2010),689171 1740-2522 - 102.
Walker D. G. Laherty R. Tomlinson F. H. Chuah T. Schmidt C. 2008 Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy,,15 2 February 2008),114 121 0967-5868 - 103.
Walker P. R. Saas P. Dietrich P. Y. 1997 Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back,,158 10 May 1997),4521 4524 0022-1767 - 104.
Walker P. R. Calzascia T. de Tribolet N. Dietrich P. Y. 2003 T-cell immune responses in the brain and their relevance for cerebral malignancies,42 2 May 2003),97 122 - 105.
Wang X. Berger C. Wong C. W. Forman S. J. Riddell S. R. Jensen M. C. 2011 Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice,,117 6 February 2011),1888 1898 0006-4971 - 106.
Watters J. J. Schartner J. M. Badie B. 2005 Microglia function in brain tumors,,81 3 August 2005),447 455 0360-4012 - 107.
Wegner M. 1999 From head to toes: the multiple facets of Sox proteins,,27 6 March 1999),1409 1420 0305-1048 - 108.
Wheeler C. J. Das A. Liu G. Yu J. S. Black K. L. 2004 Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination,,10 16 August 2004),5316 5326 1078-0432 - 109.
Wheeler C. J. Black K. L. Liu G. Mazer M. Zhang X. X. Pepkowitz S. Goldfinger D. Ng H. Irvin D. Yu J. S. 2008 Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients,,68 14 July 2008),5955 5964 0008-5472 - 110.
Wherry E. J. Teichgraber V. Becker T. C. Masopust D. Kaech S. M. Antia R. von Andrian. U. H. Ahmed R. 2003 Lineage relationship and protective immunity of memory CD8 T cell subsets,,4 3 March 2003),225 234 1529-2908 - 111.
Wikstrand C. J. Bigner D. D. 1980 Immunobiologic aspects of the brain and human gliomas. A review,,98 2 February 1980),517 568 0002-9440 - 112.
Wintterle S. Schreiner B. Mitsdoerffer M. Schneider D. Chen L. Meyermann R. Weller M. Wiendl H. 2003 Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis,,63 21 November 2003),7462 7467 0008-5472 - 113.
Wood G. W. Holladay F. P. Turner T. Wang Y. Y. Chiga M. 2000 A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma,,48 2 June 2000),113 120 0016-7594 X - 114.
Yajima N. Yamanaka R. Mine T. Tsuchiya N. Homma J. Sano M. Kuramoto T. Obata Y. Komatsu N. Arima Y. Yamada A. Shigemori M. Itoh K. Tanaka R. 2005 Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma,,11 16 August 2005),5900 5911 1078-0432 - 115.
Yamanaka R. Abe T. Yajima N. Tsuchiya N. Homma J. Kobayashi T. Narita M. Takahashi M. Tanaka R. 2003 Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial,,89 7 October 2003),1172 1179 0007-0920 - 116.
Yamanaka R. Homma J. Yajima N. Tsuchiya N. Sano M. Kobayashi T. Yoshida S. Abe T. Narita M. Takahashi M. Tanaka R. 2005 Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial,,11 11 June 2005),4160 4167 1078-0432 - 117.
Yang S. Luca G. Liu F. Ji Y. Yu Z. Restifo N. P. Rosenberg S. A. Morgan R. A. 2011 In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells,,60 5 February 2011), pp. pp. 739-7490340-7004 - 118.
Yu J. S. Wheeler C. J. Zeltzer P. M. Ying H. Finger D. N. Lee P. K. Yong W. H. Incardona F. Thompson R. C. Riedinger M. S. Zhang W. Prins R. M. Black K. L. 2001 Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration,,61 3 February 2001),842 847 0008-5472 - 119.
Yu J. S. Liu G. Ying H. Yong W. H. Black K. L. Wheeler C. J. 2004 Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma,,64 14 July 2004),4973 4979 0008-5472 - 120.
Zhang J. G. Eguchi J. Kruse C. A. Gomez G. G. Fakhrai H. Schroter S. Ma W. Hoa N. Minev B. Delgado C. Wepsic H. T. Okada H. Jadus M. R. 2007 Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics,,13 2 January 2007),566 575 1078-0432